Therapeutic advances in Huntington's Disease

Movement Disorders

Volumn 30, Issue 11, 2015, Pages 1539-1546

  Shannon, Kathleen M ^a   Fraint, Avram ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

Experimental therapeutics; Huntington disease; Huntington's disease; Review; Treatment

Indexed keywords

1 (2,3 DICHLOROBENZOYL) 5 METHOXY 2 METHYL 3 (2 MORPHOLINOETHYL)INDOLE; 2 [4 [1 METHYL 4 (4 PYRIDINYL) 3 PYRAZOLYL]PHENOXYMETHYL]QUINOLINE; ABRINEURIN; AMANTADINE; BN 82451B; BUTYRIC ACID; CEFTRIAXONE; CLONAZEPAM; CREATINE; DEUTETRABENAZINE; EPIGALLOCATECHIN GALLATE; ETIRACETAM; GANGLIOSIDE GM1; HYDROXYQUINOLINE; LAQUINIMOD; MAVOGLURANT; MERCAPTAMINE; NOOTROPIC AGENT; PAROXETINE; PLACEBO; PRIDOPIDINE; RAPAMYCIN; RESVERATROL; RILUZOLE; ROSIGLITAZONE; SELISISTAT; TETRABENAZINE; UBIDECARENONE; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT; UBIQUINONE; VITAMIN;

ANIMAL MODEL; CHOREA; DISEASE COURSE; DYSTONIA; EMOTIONAL DISORDER; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; IRRITABILITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); GENETICS; HUNTINGTON DISEASE; METABOLISM;

CLINICAL TRIALS AS TOPIC; CREATINE; HUMANS; HUNTINGTON DISEASE; UBIQUINONE; VITAMINS;

EID: 84941569159     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26331     Document Type: Review

References (92)

1. Frank S. Treatment of Huntington's disease. Neurotherapeutics 2014;11:153-160.
2. Cepeda C, Murphy KP, Parent M, Levine MS. The role of dopamine in Huntington's disease. Prog Brain Res 2014;211:235-254.
3. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;72:971-983.
4. Chiang MC, Lee YC, Huang CL, Chern Y. cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues. J Biol Chem 2005;280:14331-14340.
5. Rigamonti D, Bauer JH, De-Fraja C, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000;20:3705-3713.
6. Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007;81:294-330.
7. Smith R, Bacos K, Fedele V, et al. Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion. Hum Mol Genet 2009;18:3942-3954.
8. Tian J, Yan YP, Zhou R, Lou HF, Rong Y, Zhang BR. Soluble N-terminal fragment of mutant Huntingtin protein impairs mitochondrial axonal transport in cultured hippocampal neurons. Neurosci Bull 2014;30:74-80.
9. Nasir J, Floresco SB, O'Kusky JR, et al. Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995;81:811-823.
10. Juenemann K, Weisse C, Reichmann D, Kaether C, Calkhoven CF, Schilling G. Modulation of mutant huntingtin N-terminal cleavage and its effect on aggregation and cell death. Neurotoxicity Res 2011;20:120-133.
11. Ratovitski T, Gucek M, Jiang H, et al. Mutant huntingtin N-terminal fragments of specific size mediate aggregation and toxicity in neuronal cells. J Biol Chem 2009;284:10855-10867.
12. Legleiter J, Mitchell E, Lotz GP, et al. Mutant huntingtin fragments form oligomers in a polyglutamine length-dependent manner in vitro and in vivo. J Biol Chem 2010;285:14777-14790.
13. Cha JH. Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007;83:228-248.
14. Sharma M, Deogaonkar M. Deep brain stimulation in Huntington's disease: Assessment of potential targets. J Clin Neurosci 2015;22:812-817.
15. Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci 2009;29:3200-3205.
16. Gil-Mohapel J, Brocardo PS, Christie BR. The role of oxidative stress in Huntington's disease: Are antioxidants good therapeutic candidates? Curr Drug Targets 2014;15:454-468.
17. Smith GA, Rocha EM, McLean JR, et al. Progressive axonal transport and synaptic protein changes correlate with behavioral and neuropathological abnormalities in the heterozygous Q175 KI mouse model of Huntington's disease. Hum Mol Genet 2014;23:4510-4527.
18. Nithianantharajah J, Hannan AJ. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. Neuroscience 2013;251:66-74.
19. Wild EJ, Tabrizi SJ. Targets for future clinical trials in Huntington's disease: what's in the pipeline? Mov Disord 2014;29:1434-1445.
20. Andre VM, Cepeda C, Levine MS. Dopamine and glutamate in Huntington's disease: A balancing act. CNS Neurosci Ther 2010;16:163-178.
21. Huntington Study Group. Announcement of 2CARE early study closure. 2014.
22. Huntington Study Group. Announcement of CREST-E Early Study Closure. [cited 20xx Month xx]. Available from: http://www.huntington-study-group.org/CurrentClinicalTrials/CRESTE/CRESTEOctober2014PressRelease/tabid/316/Default.aspx2014 (accessed 7/15/2015).
23. Pharmaceuticals R. Raptor announces clinical results with RP103 in Huntington's disease phase 2/3 Trial. [cited 20xx Month xx]. Available from: http://ir.raptorpharma.com/releasedetail.cfm?releaseid=8269622014 (accessed 7/15/2015).
24. Reilmann R, Squitieri F, Priller J, et al. Safety and tolerability of selisistat for the treatment of Huntington's disease: results from a randomized, double-blind, placebo-controlled phase II trial. Philadelphia, PA: American Academy of Neurology; 2014.
25. Huntington Study Group Reach HDI. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2015;14:39-47.
26. Rosas HD, Doros G, Gevorkian S, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 2014;82:850-857.
27. Berg D, Godau J, Trenkwalder C, et al. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 2011;26:1243-1250.
28. Schiefer J, Sprunken A, Puls C, et al. The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington's disease. Brain Res 2004;1019:246-254.
29. Reilmann R, Rouzade-Dominguez ML, Saft C, et al. A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Mov Disord 2015;30:427-431.
30. Huntington Study Group HI. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord 2013;28:1407-1415.
31. Beglinger LJ, Adams WH, Langbehn D, et al. Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord 2014;29:401-405.
32. Sesok S, Bolle N, Kobal J, Bucik V, Vodusek DB. Cognitive function in early clinical phase huntington disease after rivastigmine treatment. Psychiatria Danubina 2014;26:239-248.
33. Ligot N, Krystkowiak P, Simonin C, et al. External globus pallidus stimulation modulates brain connectivity in Huntington's disease. J Cereb Blood Flow Metabol 2011;31:41-46.
34. Lopez-Sendon Moreno JL, Garcia-Caldentey J, Regidor I, del Alamo M, Garcia de Yebenes J. A 5-year follow-up of deep brain stimulation in Huntington's disease. Parkinsonism Relat Disord 2014;20:260-261.
35. 1, Capiluppi E, Saleh C, Romano L, Servello D, Mariani C, Porto M. Bilateral globus pallidus stimulation in Westphal variant of Huntington disease. Neuromodulation 2013;17:502-505.
36. Gruber D, Kuhn AA, Schoenecker T, et al. Quadruple deep brain stimulation in Huntington's disease, targeting pallidum and subthalamic nucleus: case report and review of the literature. J Neural Transm 2014;121:1303-1312.
37. Gonzalez V, Cif L, Biolsi B, et al. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study. J Neurosurg 2014;121:114-122.
38. Barker RA, Mason SL, Harrower TP, et al. The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. J Neurol Neurosurg Psychiatry 2013;84:657-665.
39. Cicchetti F, Lacroix S, Cisbani G, et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol 2014;76:31-42.
40. Cisbani G, Cicchetti F. The fate of cell grafts for the treatment of Huntington's disease: the post-mortem evidence. Neuropathol Appl Neurobiol 2014;40:71-90.
41. Bachoud-Levi AC, Gaura V, Brugieres P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006;5:303-309.
42. Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31:127-133.
43. Armstrong MJ, Miyasaki JM, American Academy of Neurobiology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79:597-603.
44. Killoran A, Biglan KM. Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? Mov Disord 2014;29:1404-1413.
45. Reilmann R. Pharmacological treatment of chorea in Huntington's disease: good clinical practice versus evidence-based guideline. Mov Disord 2013;28:1030-1033.
46. Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman L. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. PLoS Curr 2011;3:RRN1260.
47. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008;5:181-197.
48. Bonelli RM, Niederwieser G, Diez J, Gruber A, Koltringer P. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease. Clin Neuropharmacol 2002;25:58-60.
49. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry 1998;65:577-579.
50. Groves M, van Duijn E, Anderson K, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease. PLoS Curr 2011;3:RRN1259.
51. Vattakatuchery JJ, Kurien R. Acetylcholinesterase inhibitors in cognitive impairment in Huntington's disease: A brief review. World J Psychiatry 2013;3:62-64.
52. Garriga-Canut M, Agustin-Pavon C, Herrmann F, Sánchez A, Dierssen M, Fillat C, Isalan M. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A 2012;109:E3136-E3145.
53. Carroll JB, Warby SC, Southwell AL, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther 2011;19:2178-2185.
54. Stanek LM, Yang W, Angus S, et al. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. J Huntington's Dis 2013;2:217-228.
55. Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum Gene Ther 2014;25:461-474.
56. Niewoehner J, Bohrmann B, Collin L, et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014;81:49-60.
57. Kalonia H, Mishra J, Kumar A. Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats. Neurotox Res 2012;22:310-320.
58. Bantubungi K, Jacquard C, Greco A, et al. Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis 2005;18:206-217.
59. Huntington Study Group DI. A futility study of minocycline in Huntington's disease. Mov Disord 2010;25:2219-2224.
60. Di Pardo A, Maglione V, Alpaugh M, et al. Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci U S A 2012;109:3528-3533.
61. Qin ZH, Gu ZL. Huntingtin processing in pathogenesis of Huntington disease. Acta Pharmacologica Sinica 2004;25:1243-1249.
62. Hay DG, Sathasivam K, Tobaben S, et al. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Hum Mol Genet 2004;13:1389-1405.
63. Jia H, Kast RJ, Steffan JS, Thomas EA. Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems. Hum Mol Genet 2012;21:5280-5293.
64. Koga H, Martinez-Vicente M, Arias E, Kaushik S, Sulzer D, Cuervo AM. Constitutive upregulation of chaperone-mediated autophagy in Huntington's disease. J Neurosci 2011;31:18492-18505.
65. Ehrnhoefer DE, Duennwald M, Markovic P, et al. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 2006;15:2743-2751.
66. Tanaka M, Machida Y, Niu S, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 2004;10:148-154.
67. Wang N, Lu XH, Sandoval SV, Yang XW. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease. J Huntington's Dis 2013;2:443-451.
68. Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genet 2004;36:585-595.
69. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mTOR-independent autophagy inducers ameliorate toxicity of polyglutamine-expanded huntingtin and related proteinopathies. Cell Death Differ 2009;16:46-56.
70. Giampa C, Laurenti D, Anzilotti S, Bernardi G, Menniti FS, Fusco FR. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease. PloS One 2010;5:e13417.
71. Fan J, Gladding CM, Wang L, et al. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiology of disease 2012;45:999-1009.
72. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003;23:9418-9427.
73. Zuccato C, Ciammola A, Rigamonti D, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001;293:493-498.
74. Giampa C, Montagna E, Dato C, Melone MA, Bernardi G, Fusco FR. Systemic delivery of recombinant brain derived neurotrophic factor (BDNF) in the R6/2 mouse model of Huntington's disease. PloS One 2013;8:e64037.
75. Silva A, Naia L, Dominguez A, et al. Overexpression of BDNF and full-length TrkB receptor ameliorate striatal neural survival in Huntington's disease. Neurodegener Dis 2015 (online in advance of print, April 21, 2015).
76. Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 2010;30:14708-14718.
77. Squitieri F, Orobello S, Cannella M, et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging 2009;36:1113-1120.
78. Simmons DA, Mehta RA, Lauterborn JC, Gall CM, Lynch G. Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. Neurobiol Dis 2011;41:436-444.
79. Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 2004;55:590-594.
80. Borrell-Pages M, Canals JM, Cordelieres FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006;116:1410-1424.
81. Mao Z, Choo YS, Lesort M. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur J Neurosci 2006;23:1701-1710.
82. Prundean A, Youssov K, Humbert S, Bonneau D, Verny C. A phase II, open-label evaluation of cysteamine tolerability in patients with Huntington's disease. Mov Disord 2015;30:288-289.
83. Jiang M, Peng Q, Liu X, et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum Mol Genet 2013;22:2462-2470.
84. Simmons DA, Belichenko NP, Yang T, et al. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J Neurosci 2013;33:18712-18727.
85. Todd D, Gowers I, Dowler SJ, et al. A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease. PLoS One 2014;9:e87923.
86. Zadori D, Nyiri G, Szonyi A, et al. Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J Neural Transm 2011;118:865-875.
87. Bruck W, Pfortner R, Pham T, et al. Reduced astrocytic NF-kappaB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol 2012;124:411-424.
88. Bouchard J, Truong J, Bouchard K, et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci 2012;32:18259-18268.
89. Sari Y, Prieto AL, Barton SJ, Miller BR, Rebec GV. Ceftriaxone-induced up-regulation of cortical and striatal GLT1 in the R6/2 model of Huntington's disease. J Biomed Sci 2010;17:62.
90. Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem 2008;283:25628-25637.
91. Pietropaolo S, Bellocchio L, Ruiz-Calvo A, et al. Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease. Neuropharmacology 2015;89:368-374.
92. Sandhir R, Mahajan N, Mehrotra A, Aggarwal A, Sunkaria A. 4-Hydroxy tempo improves mitochondrial and neurobehavioral deficits in experimental model of Huntington's disease. Synapse 2015;69:128-138.